Display options
Cite
Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh HA, et al. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Exp Ther Med. 2016;12(2):815-822doi: 10.3892/etm.2016.3395.
Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H. A., Skrypnyk, C., Sabry, M. A., & Ramadan, A. R. (2016). Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Experimental and therapeutic medicine, 12(2), 815-822. https://doi.org/10.3892/etm.2016.3395
Al-Kafaji, Ghada, et al. "Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker." Experimental and therapeutic medicine vol. 12,2 (2016): 815-822. doi: https://doi.org/10.3892/etm.2016.3395
Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh HA, Skrypnyk C, Sabry MA, Ramadan AR. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Exp Ther Med. 2016 Aug;12(2):815-822. doi: 10.3892/etm.2016.3395. Epub 2016 May 26. PMID: 27446281; PMCID: PMC4950785.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2016 Aug;12(2):815-822. doi: 10.3892/etm.2016.3395. Epub 2016 May 26.

Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker.

Experimental and therapeutic medicine

Ghada Al-Kafaji, Ghazi Al-Mahroos, Haifa Abdulla Al-Muhtaresh, Cristina Skrypnyk, Mohamed Abdalla Sabry, Ahmad R Ramadan

Affiliations

  1. Department of Molecular Medicine/Al-Jawhara Centre for Molecular Medicine, Genetics and Inherited Disorders, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain.
  2. Diabetes and Endocrinology Clinic, Salmaniya Medical Complex, Manama 12, Kingdom of Bahrain.
  3. Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 26671, Kingdom of Bahrain.
  4. Department of Life Sciences, Medical Biotechnology, College of Graduate Studies, Arabian Gulf University, Manama 26671, Kingdom of Bahrain.

PMID: 27446281 PMCID: PMC4950785 DOI: 10.3892/etm.2016.3395

Abstract

Circulating microRNAs (miRNAs) have been proposed as promising biomarkers for multiple diseases. miR-126 is reported to be associated with type 2 diabetes mellitus (T2D), diabetic nephropathy (DN) and end stage renal disease. The aim of this study was to investigate the expression of circulating miR-126 and to assess its potential as a blood-based biomarker for DN in T2D patients. In 52 patients with T2D without history of DN (with noromoalbuminuria), 50 patients with T2D and DN (29 with microalbuminuria and 21 with macroalbuminuria), and 50 non-diabetic healthy controls, the expression of circulating miR-126 in peripheral whole blood was evaluated by quantitative polymerase chain reaction. The expression levels of circulating miR-126 were significantly decreased in T2D patients and further decreased in DN patients compared with those in the controls. Multivariate logistic regression analysis confirmed the independent association of lower miR-126 levels with T2D [adjusted odds ratio (OR), 0.797; 95% confidence interval (CI), 0.613-0.960] and DN (adjusted OR, 0.513; 95% CI, 0.371-0.708). miR-126 levels were associated with the degree of albuminuria and showed significantly low expression in DN patients with microalbuminuria (adjusted OR, 0.781; 95% CI; 0.698-0.952) and further lower expression in DN patients with macroalbuminuria (adjusted OR, 0.433; 95% CI, 0.299-0.701), respectively compared with T2D patients with normoalbuminuria. miR-126 levels negatively correlated with albuminuria positively with glomerular filtration rate (P<0.05), and in addition, negatively correlated with fasting glucose, glycated hemoglobin, triglyceride and LDL (P<0.05). Stepwise multiple regression analysis identified albuminuria as a significant predictor of miR-126 (P<0.001). miR-126 in peripheral blood yielded area under the receiver operating characteristic curves of 0.854 (95% CI, 0.779-0.929) and 0.959 (95% CI, 0.916-1.000) in the differentiation of DN patients from T2D patients and DN patients from non-diabetic controls respectively. These data suggest that decreased expression of circulating miR-126 is associated with the development of DN in T2D patients, and may be a promising blood-based biomarker for DN risk estimation.

Keywords: biomarker; circulating miRNAs; diabetic nephropathy; miR-126; type 2 diabetes mellitus

References

  1. Mutat Res. 2011 Dec 1;717(1-2):85-90 - PubMed
  2. Nephrol Dial Transplant. 2002 Nov;17(11):2036-7 - PubMed
  3. Diabet Med. 1998 Jul;15(7):539-53 - PubMed
  4. Nephrol Dial Transplant. 2000 Dec;15(12):1900-2 - PubMed
  5. Basic Res Cardiol. 2011 Jan;106(1):13-23 - PubMed
  6. Diabetes Care. 2014;37(5):1375-83 - PubMed
  7. Nat Cell Biol. 2007 Jun;9(6):654-9 - PubMed
  8. J Intern Med. 2001 Jun;249(6):519-26 - PubMed
  9. J Mol Cell Cardiol. 2012 Jul;53(1):64-72 - PubMed
  10. Sci Rep. 2014 May 22;4:5026 - PubMed
  11. Curr Biol. 2002 Apr 30;12(9):735-9 - PubMed
  12. Am J Kidney Dis. 2001 Aug;38(2):310-6 - PubMed
  13. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  14. Circ Res. 2010 Sep 17;107(6):810-7 - PubMed
  15. J Clin Endocrinol Metab. 2014 Sep;99(9):E1661-5 - PubMed
  16. J Korean Med Sci. 2011 Feb;26(2):258-63 - PubMed
  17. Am J Physiol Renal Physiol. 2011 Mar;300(3):F602-10 - PubMed
  18. Sci Signal. 2009 Dec 08;2(100):ra81 - PubMed
  19. Am J Transplant. 2015 Apr;15(4):1081-90 - PubMed
  20. Dev Cell. 2008 Aug;15(2):261-71 - PubMed
  21. Nat Rev Nephrol. 2010 Jun;6(6):371-80 - PubMed
  22. Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1630-9 - PubMed
  23. Clin J Am Soc Nephrol. 2009 Jul;4(7):1255-66 - PubMed
  24. Dev Cell. 2008 Aug;15(2):272-84 - PubMed
  25. N Engl J Med. 1984 Feb 9;310(6):356-60 - PubMed
  26. Avicenna J Med Biotechnol. 2010 Oct;2(4):161-79 - PubMed
  27. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1516-21 - PubMed
  28. Annu Rev Pathol. 2011;6:395-423 - PubMed
  29. Mol Med Rep. 2015 Nov;12(5):7485-90 - PubMed
  30. Int J Mol Sci. 2014 Jun 12;15(6):10567-77 - PubMed
  31. Diabetes Care. 2001 Sep;24(9):1560-6 - PubMed
  32. Cell Physiol Biochem. 2009;23(4-6):221-32 - PubMed
  33. J Biol Chem. 2010 Jun 4;285(23):17442-52 - PubMed
  34. Cardiovasc Hematol Disord Drug Targets. 2014;14(1):22-33 - PubMed
  35. Trends Cell Biol. 2012 Mar;22(3):125-32 - PubMed
  36. Clin Chem. 2010 Nov;56(11):1733-41 - PubMed
  37. Kidney Int. 2004 Oct;66(4):1596-605 - PubMed
  38. World J Diabetes. 2013 Dec 15;4(6):245-55 - PubMed
  39. Int J Endocrinol. 2014;2014:393109 - PubMed
  40. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S144-7 - PubMed
  41. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  42. J Am Soc Nephrol. 2008 Nov;19(11):2150-8 - PubMed
  43. Braz J Med Biol Res. 2012 Dec;45(12):1308-14 - PubMed
  44. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  45. Trends Cell Biol. 2007 Mar;17(3):118-26 - PubMed

Publication Types